

**Supplementary Table 1. Demographic, anthropometric, and clinical characteristics of the two groups before matching**

Characteristic	KTR group	CKD group	p-value
No. of patients	205	126	
Age (yr)	51.7 ± 12.9	66.8 ± 10.5	<0.001*
Female sex	69 (33.7)	46 (36.5)	0.6
Time since kidney transplantation (mo)	75.7 [133.5]	-	-
Body mass index (kg/m <sup>2</sup> )	26.8 ± 11.8	30.1 ± 5.9	0.001*
Hypertension	180 (87.8)	116 (92.1)	0.34
Diabetes	36 (17.6)	78 (61.9)	0.01*
Dyslipidemia	107 (52.2)	90 (71.4)	0.001*
Coronary heart disease	20 (9.8)	23 (18.4)	0.02*
Stroke	2 (1.0)	6 (4.8)	0.03*
Peripheral arterial disease	6 (2.9)	13 (10.3)	0.005*
Smoking	19 (9.3)	26 (20.6)	0.001*
Office SBP (mmHg)	129.0 ± 16.9	130.9 ± 9.2	0.19
Office DBP (mmHg)	76.5 ± 10.2	80.1 ± 7.5	<0.001*
No. of antihypertensive drugs	1.7 ± 1.1	2.6 ± 1.4	0.001*
ACEi/ARBs	85 (41.5)	80 (63.5)	0.001*
Calcium-channel blockers	84 (41.0)	80 (63.5)	<0.001*
MRAs	0 (0)	5 (4.0)	0.008*
Beta-blockers	137 (66.8)	64 (50.8)	0.004*
Alpha-blockers	2 (1.0)	20 (15.9)	<0.001*
Central acting agents	16 (7.8)	13 (10.3)	0.43
Diuretics	22 (10.7)	67 (53.2)	<0.001*
Statins	73 (35.6)	87 (69.0)	<0.001*
Immunosuppressive drugs			
Cyclosporine	28 (13.7)		
Tacrolimus	166 (81.0)		
mTORi	19 (9.3)		
MMF/MMA	189 (92.2)		
Azathioprine	3 (1.5)		
Corticosteroids	167 (81.5)		
Others	1 (0.5)		
Hemoglobin (g/dL)	13.0 ± 1.6	13.5 ± 1.5	0.005*
eGFR CKD-EPI (mL/min/1.73 m <sup>2</sup> )	57.9 ± 19.5	56.0 ± 23.9	0.45
Creatinine (mg/dL)	1.4 ± 0.5	1.4 ± 0.6	0.97
Urea (mg/dL)	60.0 ± 27.4	57.0 ± 29.0	0.35
Uric acid (mg/dL)	6.7 ± 1.4	6.5 ± 1.5	0.18
Sodium (mEq/L)	140.4 ± 2.8	138.8 ± 2.5	<0.001*
Potassium (mEq/L)	4.5 ± 0.5	4.7 ± 0.4	0.03*
Calcium (mg/dL)	9.6 ± 0.5	9.4 ± 0.6	0.02*
Phosphorus (mg/dL)	3.1 ± 0.7	3.5 ± 0.6	<0.001*
Total cholesterol (mg/dL)	194.0 ± 33.0	161.3 ± 38.8	<0.001*
Triglycerides (mg/dL)	150.9 ± 72.2	154.8 ± 90.6	0.67

Data are expressed as number only, mean ± standard deviation, or number (%), or median [interquartile range].

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; CKD-EPI, CKD-Epidemiology Collaboration; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; KTR, kidney transplant recipient; MMF, mycophenolate mofetil; MRA, mineralocorticoid receptor antagonist; mTORi, mammalian target of rapamycin inhibitors; SBP, systolic blood pressure.

\*p < 0.05 is statistically significant.